Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals (myBIOM)

tiistai 3. marraskuuta 2026 päivittänyt: Chr Hansen - part of Novonesis

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals: a Randomized, Double-blind, Placebo-controlled Study

The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults. The study includes an 8-week intervention period followed by a 2-week follow-up period. The study will evaluate the effect of a synbiotic consisting of two probiotic strains and a prebiotic.

The aim is to investigate the effect of the synbiotic on modulating the gut microbiota and improving markers of gastrointestinal permeability and integrity and gastrointestinal discomfort.

Tutkimuksen yleiskatsaus

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

90

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

    • Blackpool
      • Cork, Blackpool, Irlanti, T23 R50R
        • Rekrytointi
        • Atlantia Clinical Trials Ltd
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

45 vuotta - 70 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Be able to give informed consent.
  2. Be between 45 to 70 years of age (inclusive).
  3. BMI <40.0 kg/m²
  4. Willing to maintain current level of physical activity and diet during the participation in the study.
  5. Experience ≤4 bowel movements per week within the month prior to screening
  6. Participants reported subclinical mild to moderate gastrointestinal complaints as defined by GSRS-IBS score 20-52 at screening.
  7. Willing to consume the study product daily for the duration of the study.
  8. Willing to eat the same meal the evening before visiting site (visit 2 to visit 5).

Participants are eligible for randomization if they fulfill the following two criteria based on the diary recordings during the run-in period prior to visit 2 9. Average GSRS-IBS composite symptom score between 20-52 during the two-week run-in period Record ≤8 bowel movements in the daily diary during the two-week run-in period

Exclusion Criteria:

  1. Has a history of drug and/or alcohol abuse.

  2. Has food allergies, or other issues with foods, that would preclude intake of the study products.

  3. Smoking, chewable tobacco and/or vaping and/or use of other nicotine products.

  4. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:

    1. diagnosis of GI disease (e.g. gastric or duodenal ulcers, inflammatory bowel disease, colon cancer) or irritable bowel syndrome (IBS)
    2. GI surgery that might have an effect on gastrointestinal tract function except cholecystectomy and appendectomy in the past 5 years or any major bowel resection at any time.
    3. history of CVD
    4. uncontrolled hypertension
  5. Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:

    1. systemic antimicrobial medication (including suppositories) within 4 weeks prior to visit 1
    2. OTC medications, for digestive symptoms such as PPIs, anti-spasmodics, laxatives, anti-diarrheic drugs within 2 weeks prior to visit 1

10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.

11. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.

c. immunosuppressant drugs within the 4 weeks prior to the visit 1 d. systemic steroids within the 4 weeks prior to the visit 1 6. Regular oral non-steroidal anti-inflammatory (NSAIDs) within 1 week prior to visit 1 (topical NSAIDS allowed, Low-dose prophylactic aspirin use is acceptable if stable for 3 months prior to screening.) 7. Current or recent (in the past 4 weeks prior to visit 1) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results, including:

a. Herbal supplements for digestive symptoms b. Large doses of vitamins and minerals, unless in stable dose c. Probiotic supplements d. Iron supplements 8. Current or recent (in the past 2-weeks) use of prohibited foods including yoghurts containing probiotics.

9. Planned major changes in lifestyle [i.e., diet (e.g. start of fibre-enriched diet), dieting, exercise level, travelling] during the duration of the study.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Muut
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Active Comparator: Synbiotic

Synbiotic dietary supplement

Synbiotic

- Given daily for 56 days

Placebo Comparator: Placebo

Identical looking placebo consisting of maltodextrin

Placebo

- Given daily for 56 days

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Bifidobacterium abundance
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in total relative abundance of Bifidobacterium from baseline to 8 weeks assessed from fecal samples. Abundance is calculated based on shotgun metagenomic sequencing.

From baseline to end of intervention at 8 weeks

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Stool frequency
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in number of daily bowel movements from 2 weeks average prior to baseline to 2 weeks average prior to end of intervention. An increase is desirable.

From baseline to end of intervention at 8 weeks
Fecal acetate
Aikaikkuna: From baseline to end of intervention at 8 weeks.

Change in fecal acetate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks.
Fecal propionate
Aikaikkuna: From baseline to end of intervention at 8 weeks.

Change in fecal propionate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks.
Fecal butyrate
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in fecal butyrate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks
Zonulin
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in serum zonulin from baseline to 8 weeks

From baseline to end of intervention at 8 weeks
Lipopolysaccharide binding protein (LPS-BP)
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in plasma LPS-BP from baseline to 8 weeks

From baseline to end of intervention at 8 weeks
Interleukin 6 (IL-6)
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in serum IL-6 from baseline to 8 weeks

From baseline to end of intervention at 8 weeks
High-sensitivity C-Reactive Protein (hsCRP)
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in serum hsCRP from baseline to 8 weeks.

From baseline to end of intervention at 8 weeks
Fecal Short-Chain Fatty Acids (SCFA)
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in composite measurement of fecal SCFAs panel with targeted metabolomics (GC-MSMS) from baseline to 8 weeks. Total composite is defined as: acetate + propionate + butyrate.

From baseline to end of intervention at 8 weeks
Stool consistency
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in mean stool consistency assessed daily from 2 weeks prior to baseline to daily 2 weeks prior to end-of intervention. Stool consistency will be assessed by Bristol stool chart scale rated Type 1 (separate hard lumps) to Type 7 (watery, no solid pieces). An increase in stool consistency is desirable.

From baseline to end of intervention at 8 weeks
Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) score
Aikaikkuna: From baseline to end of intervention at 8 weeks

Change in GSRS-IBS composite score from baseline to end-of-intervention visit. The GSRS-IBS questionnaire includes 13 items that measure the severity of IBS symptoms in five clusters (pain, bloating, constipation, diarrhea and early satiety) during the last seven days. A decrease is desirable.

From baseline to end of intervention at 8 weeks

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Recovery of probiotic strains
Aikaikkuna: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Recovery and colonization of strains by strain specific qPCR of fecal samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Total relative abundance of Bifidobacterium
Aikaikkuna: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.

Change in total relative abundance of Bifidobacterium after 2 weeks of follow-up (no intervention) compared to effect after 3 weeks and 8 weeks of intervention.

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.
Microbiome composition and taxonomic profiles
Aikaikkuna: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Changes in gut microbiome composition and taxonomic profiling analyzed by shotgun metagenomic sequencing of fecal samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Microbiome functional profiling
Aikaikkuna: Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in gut microbiome functional profiling analyzed by shotgun metagenomic sequencing of fecal samples

Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Plasma Metabolomics
Aikaikkuna: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in blood metabolome as assessed by untargeted and targeted metabolomics from plasma samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Fecal metabolomics
Aikaikkuna: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in fecal metabolome as assessed by untargeted and targeted metabolomics from fecal samples

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
Bacterial HMO utilization genes
Aikaikkuna: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Abundance development over time of HMO degradation and modification genes such as Glycosyl hydrolases, encoded by probiotic supplements and endogenous gut species

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
HMO concentration in blood and feces
Aikaikkuna: Baseline, 3 weeks and end of intervention at 8 weeks

Change in HMO in plasma and fecal samples after 3 and 8 weeks of supplementation

Baseline, 3 weeks and end of intervention at 8 weeks
Fecal pH
Aikaikkuna: Baseline, 3 weeks and end of intervention at 8 weeks

Change in pH assessed using a pH meter in fecal samples

Baseline, 3 weeks and end of intervention at 8 weeks
Inflammatory Biomarkers
Aikaikkuna: Baseline, 3 weeks and end of intervention at 8 weeks

Change in inflammatory biomarkers measured in serum

Baseline, 3 weeks and end of intervention at 8 weeks
Cardiometabolic Biomarkers
Aikaikkuna: Baseline, 3 weeks and end of intervention at 8 weeks

Change in cardiometabolic biomarkers

Baseline, 3 weeks and end of intervention at 8 weeks
Cognitive function measured by the Trails Making Test (Parts A & B)
Aikaikkuna: Baseline and end of intervention at 8 weeks

Change in cognitive function assessed using Trail Making Test (Parts A & B)

Baseline and end of intervention at 8 weeks
Cognitive function measured by the Stroop Colour and Word Test
Aikaikkuna: Baseline and end of intervention at 8 weeks

Change in cognitive function assessed using the Stroop Colour and Word Test

Baseline and end of intervention at 8 weeks
Cognitive function measured by the Symbol Digit Modalities Test (SDMT)
Aikaikkuna: Baseline and end of intervention at 8 weeks

Change in cognitive function assessed using the Symbol Digit Modalities Test (SDMT)

Baseline and end of intervention at 8 weeks
Health-related Quality of Life
Aikaikkuna: Baseline, 3 weeks and end of intervention at 8 weeks

Change in health-related quality of life assessed by Short Form-36 (RAND SF-36)

Baseline, 3 weeks and end of intervention at 8 weeks
Gastrointestinal Symptoms Measured by the GSRS-IBS Total Score
Aikaikkuna: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up

Change in gastrointestinal symptoms by assessing the Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS). The outcome reflects the total composite score. A decrease is desirable.

Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
GSRS-IBS Pain Subscale
Aikaikkuna: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.

Change in the gastrointestinal symptom pain assessed using GSRS-IBS subscale for Pain. A decrease is desirable.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.
GSRS-IBS Bloating Subscale
Aikaikkuna: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom bloating assessed using GSRS-IBS subscale for bloating. A decrease is desirable.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
GSRS-IBS Constipation Subscale
Aikaikkuna: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom constipation assessed using GSRS-IBS subscale for constipation. A decrease is desirable

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
GSRS-IBS Diarrhea Subscale
Aikaikkuna: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom Diarrhea assessed using GSRS-IBS subscale for Diarrhea. A decrease is desirable.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
GSRS-IBS Early Satiety Subscale
Aikaikkuna: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up

Change in the gastrointestinal symptom early satiety assessed using GSRS-IBS subscale for early satiety.

Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
Protein Composite Score
Aikaikkuna: Baseline, 3 weeks and end of intervention at 8 weeks

Change in protein composite score measured using OLINK Reveal panel

Baseline, 3 weeks and end of intervention at 8 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Martin Buckley, Professor, Atlantia Clinical Trials Ltd

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 18. maaliskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Perjantai 1. lokakuuta 2027

Opintojen valmistuminen (Arvioitu)

Perjantai 1. lokakuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 24. helmikuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Sunnuntai 1. maaliskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Perjantai 6. maaliskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 6. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 3. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • HHB-GI-2406
  • ECM4(i)11/12/2025 (Muu tunniste: Clinical Research Ethics Committee of the Cork Teaching Hospitals)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa